Q-omics provides the consensus-scored ZBTB8OSP2 profile across patient tissues and cancer cell-line models. ZBTB8OSP2 expression is associated with patient survival in 18 of 34 cancer types, with the highest sampling consensus in THCA. Among the 18 cancer types available for tumor–normal comparison, ZBTB8OSP2 is differentially expressed in 4, with the highest sampling consensus in PAAD. Additionally, ZBTB8OSP2 RNA expression shows 5,737 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight THCA, PAAD, and STAD as cancer lineages where ZBTB8OSP2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ZBTB8OSP2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ZBTB8OSP2 survival associations across molecular data types. ZBTB8OSP2 RNA expression shows survival associations in the most cancer types (18). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ZBTB8OSP2 RNA expression–survival associations across cancer types. High ZBTB8OSP2 expression shows unfavorable associations in UVM, ACC, UCEC and DLBC, but favorable associations in THCA and LUAD. The THCA Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .004). Together, the overview and detailed table identify THCA as the clearest survival context for ZBTB8OSP2 RNA expression.
This table summarizes ZBTB8OSP2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 4. The strongest signals are observed in PAAD for RNA.
This table ranks reproducible tumor–normal expression differences for ZBTB8OSP2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ZBTB8OSP2 shows lower tumor expression in PAAD and KICH and higher tumor expression in HNSC and CHOL. The PAAD box plot shows higher ZBTB8OSP2 RNA expression in normal versus tumor tissue (log2 FC = −0.185, t-test p = .006).
This table shows molecular features associated with ZBTB8OSP2 in patient tissues and cancer cell lines. In patient samples, ZBTB8OSP2 shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set.
